全文获取类型
收费全文 | 453篇 |
免费 | 16篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 39篇 |
妇产科学 | 2篇 |
基础医学 | 108篇 |
口腔科学 | 4篇 |
临床医学 | 51篇 |
内科学 | 111篇 |
皮肤病学 | 1篇 |
神经病学 | 31篇 |
特种医学 | 20篇 |
外科学 | 66篇 |
综合类 | 1篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 25篇 |
肿瘤学 | 11篇 |
出版年
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 4篇 |
2017年 | 4篇 |
2015年 | 3篇 |
2014年 | 7篇 |
2013年 | 7篇 |
2012年 | 7篇 |
2011年 | 12篇 |
2010年 | 9篇 |
2009年 | 8篇 |
2008年 | 15篇 |
2007年 | 19篇 |
2006年 | 11篇 |
2005年 | 19篇 |
2004年 | 20篇 |
2003年 | 26篇 |
2002年 | 25篇 |
2001年 | 23篇 |
2000年 | 26篇 |
1999年 | 16篇 |
1998年 | 8篇 |
1997年 | 9篇 |
1996年 | 11篇 |
1995年 | 13篇 |
1994年 | 8篇 |
1993年 | 8篇 |
1992年 | 25篇 |
1991年 | 20篇 |
1990年 | 15篇 |
1989年 | 12篇 |
1988年 | 12篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1975年 | 2篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1972年 | 3篇 |
1967年 | 1篇 |
1966年 | 1篇 |
1965年 | 1篇 |
1917年 | 1篇 |
排序方式: 共有474条查询结果,搜索用时 0 毫秒
471.
We experienced anesthetic managements of four patients with Fournier syndrome. In the anesthetic management of the patients with Fournier syndrome the following three points should be kept in mind; (a) the necessity of careful preoperative examination, (b) the better anesthesia, and (c) the careful postoperative care. 相似文献
472.
Tomatsu S Sukegawa K Trandafirescu GG Gutierrez MA Nishioka T Yamaguchi S Orii T Froissart R Maire I Chabas A Cooper A Di Natale P Gal A Noguchi A Sly WS 《European journal of human genetics : EJHG》2006,14(7):838-845
Hunter syndrome, an X-linked disorder, results from deficiency of iduronate-2-sulfatase (IDS). Around 40% of independent point mutations at IDS were found at CpG sites as transitional events. The 15 CpG sites in the coding sequences of exons 1 and 2, which are normally hypomethylated, account for very few of transitional mutations. By contrast, the CpG sites in the coding sequences of exon 3, though also normally hypomethylated, account for much higher fraction of transitional mutations. To better understand relationship between methylation status and CpG transitional mutations in this region, the methylation patterns of 11 Hunter patients with transitional mutations at CpG sites were investigated using bisulfite genomic sequencing. The patient cohort mutation spectrum is composed of one mutation in exon 1 (one patient) and three different mutations in exon 3 (10 patients). We confirmed that in normal males, cytosines at the CpG sites from the promoter region to a portion of intron 3 were hypomethylated. However, specific CpG sites in this area were more highly methylated in patients. The patients with p.R8X (exon 1), p.P86L (exon 3), and p.R88H (exon 3) mutations had a hypermethylated condition in exon 2 to intron 3 but retained hypomethylation in exon 1. The same trend was found in four patients with p.A85T (exon 3), although the degree of hypermethylation was less. These findings suggest methylation patterns in the beginning of IDS genomic region are polymorphic in humans and that hypermethylation in this region in some individuals predisposes them to CpG mutations resulting in Hunter syndrome. 相似文献
473.
Tomatsu S Montaño AM Oikawa H Smith M Barrera L Chinen Y Thacker MM Mackenzie WG Suzuki Y Orii T 《Current pharmaceutical biotechnology》2011,12(6):931-945
Mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A, is a rare, autosomal recessive disorder caused by a deficiency of the lysosomal enzyme N-acetylgalatosamine-6-sulfate-sulfatase (GALNS), which catalyzes a step in the catabolism of glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-sulfate (C6S). It leads to accumulation of the KS and C6S, mainly in bone and cornea, causing a systemic skeletal chondrodysplasia. MPS IVA has a variable age of onset and variable rate of progression. Common presenting features include elevation of urinary and blood KS, marked short stature, hypoplasia of the odontoid process, pectus carinatum, kyphoscoliosis, genu valgum, laxity of joints and corneal clouding; however there is no central nervous system impairment. Generally, MPS IVA patients with a severe form do not survive beyond the third decade of life whereas those patients with an attenuated form may survive over 70 years. There has been no effective therapy for MPS IVA, and care has been palliative. Enzyme replacement therapy (ERT) and hematopoietic stem cell therapy (HSCT) have emerged as a treatment for mucopolysaccharidoses disorders, including Morquio A disease. This review provides an overview of the clinical manifestations, diagnosis and symptomatic management of patients with MPS IVA and describes potential perspectives of ERT and HSCT. The issue of treating very young patients is also discussed. 相似文献
474.